According to the latest study titled ‘Connected Drug Delivery Devices Market Size By Device Type [Connected Sensors {Connected Inhalation Sensors, Connected Injectable Sensors}, Integrated Devices {Integrated Inhalation Devices, Integrated Injectable Devices,}], By Technology [Bluetooth, Near Field Communication, Wi-Fi], By Application [Anaphylaxis, Respiratory, Cardiovascular, Diabetes, Hormone Replacement], By End-use [Hospital, Clinics, Homecare], COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global connected drug delivery devices market is expected to grow significantly during the forecast period 2021-2027.

 

Prevalence of chronic ailment cases, patient preference for home-based care, and enhance drug delivery efficacy of these devices are primarily driving the growth of global connected drug delivery devices market.

 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4202297/

 

Moreover, rising patient consciousness about medication adherence, accelerated adoption of machine learning and artificial intelligence (AI), continually advancing healthcare IT infrastructure, and increasing integration of telehealth portals connected with AR/VR technologies will further impel the industry share.

 

Despite the positive outlook, privacy concerns regarding patient information, and huge costs associated with the devices are likely to hamper industry development in the coming years.

 

Based on device type, connected sensors segment was valued at USD 117.5 million in the year 2020 and is estimated to grow substantially during the forecast period. 

 

In terms of application, worldwide connected drug delivery devices industry share from anaphylaxis segment is projected to exhibit a valuation of USD 224.9 million by the year 2027.

 

Concerning technology, the near-field communication technology segment accounted for a market share of 28.7% in 2020 and is anticipated to upsize over the analysis period. 

 

Speaking of end-use scope, the clinics segment share is poised to witness a 35.3% CAGR over the assessment timeline.

 

From a regional standpoint, Latin America held nearly 9.9% revenue share in 2020. Meanwhile, Middle East & Africa market is anticipated to grow at 35.9% CAGR through 2027.

 

The competitive landscape of global connected drug delivery devices market is defined by companies such as West Pharmaceutical Services Inc., Phillips-Medisize Corp., FindAir Sp. z o.o., Adherium Limited, Propeller Health, Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Nemera, and BioCorp Production S.A. among others.